Cargando…
Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
BACKGROUND: Bone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2‐positive breast cancer with bone metastases require further investigation. The goal of this retrospective study w...
Autores principales: | Lyu, Xiaoshuang, Luo, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607243/ https://www.ncbi.nlm.nih.gov/pubmed/34612593 http://dx.doi.org/10.1002/cam4.4326 |
Ejemplares similares
-
HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2‐negative patients
por: Si, Pilei, et al.
Publicado: (2017) -
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
por: Yap, Y S, et al.
Publicado: (2012) -
Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases
por: Parkes, Amanda, et al.
Publicado: (2018) -
Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis
por: Niikura, Naoki, et al.
Publicado: (2011) -
Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)